The protein vimentin triggers autoimmune reactions in people with idiopathic pulmonary fibrosis (IPF), and the intensity of the reactions correlates with…
Articles by Patricia Inácio, PhD
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to SM04646, a therapy developed by San…
Australia’s national registry of patients with idiopathic pulmonary fibrosis (IPF) includes patients of diverse ages, disease severity and co-morbidities, and shows…
Esbriet (pirfenidone) stops the lung scarring in idiopathic pulmonary fibrosis (IPF) by improving the functioning of mitochondria, cell components that convert…
Lung Therapeutics announced June 6 that it has completed a $14.3 million Series B financing round to support development of LTI-03, its…
Natural gene variants, called polymorphisms, may explain why some patients with systemic sclerosis also develop pulmonary fibrosis (PF). The study,…
An investigative therapy for idiopathic pulmonary fibrosis (IPF) based on inhibiting two proteins, including the cannabinoid CB1 receptor, shows potential for…
Antacid therapy (AAT) may lead to major digestive problems and severe lung infections in idiopathic pulmonary fibrosis (IPF) patients who…
A new imaging strategy shows promising results in improving the diagnosis and treatment of people with pulmonary fibrosis (PF). The…
Using Esbriet (pirfenidone) or Ofev (nintedanib) for a year reduces lung function decline in idiopathic pulmonary fibrosis (IPF) patients,…